Method of treating hyperglycemia

• US 9,980,935 B2
• Filed: 05/17/2017
• Issued: 05/29/2018
• Est. Priority Date: 05/20/2016
• Status: Active Grant

• Current Assignee: Center Laboratories, Inc.
• Original Assignee: Center Laboratories, Inc.
• Inventors: Hsu, Jui-Pao, Shane, Guang-Tzuu, Lee, Meng-Ju, Liao, Yi-Ping, Yeh, Yu-Yin
• Primary Examiner(s): Klinkel, Kortney L.
• Assistant Examiner(s): Strong, Tori
• Application Number:
  US15/597,200
• Publication Number:
  US 20170333382A1
• Time in Patent Office: 377 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.

Claims

1. A method of treating a subject having diabetes mellitus and/or disorders related to diabetes mellitus comprising administering to the subject an effective amount of (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and biguanide so as to reduce the blood glucose level of the subject.

2. The method of claim 1, wherein the biguanide is metformin, phenformin, or bufomin.

3. The method of claim 1, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is in crystalline form.

4. The method of claim 3, wherein the (R)-(+)-verapamil exists in a hydrochloride salt.

5. The method of claim 4, wherein the (R)-(+)-verapamil hydrochloride is administered to the subject in the amount of 15 to 1,000 mg/day.

6. The method of claim 5, wherein the (R)-(+)-verapamil hydrochloride is administered to the subject in the amount of 25 to 800 mg/day.